ASLAN Pharmaceuticals Pte Ltd
10A Bukit Pasoh Road
148 articles with ASLAN Pharmaceuticals Pte Ltd
ASLAN Pharmaceuticals announced today the appointment of Robert E. Hoffman as an Independent Non-Executive Director. Mr. Hoffman has more than 20 years of experience in leading and managing global biotechnology companies, and working with a number of public, late-stage oncology companies.
NEW DATA PRESENTED ON ASLAN’S VARLITINIB AT ESMO SHOW PROMISING RESULTS IN HEAVILY PRE-TREATED BTC AND CRC PATIENTS
ASLAN Pharmaceuticals today announced the presentation of new data from an ongoing phase 1 study to determine the safety, tolerability and maximum tolerated dose (MTD) of varlitinib in combination with oxaliplatin and capecitabine (COX) or oxaliplatin and 5-FU (FOL) in advanced solid tumours.
ASLAN PHARMACEUTICALS TO PRESENT POSTERS ON VARLITINIB AND ASLAN003 AT EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS
The investigator-initiated trial was conducted by Dr Matthew Chau Hsien Ng and supported by ASLAN and the Singapore National Medical Research Council.
ASLAN PHARMACEUTICALS PROVIDES UPDATE ON TIMELINES FOR CLINICAL TRIAL OF VARLITINIB IN BILIARY TRACT CANCER IN CHINA
Management will host a conference call and webcast today, Monday, 17 September at 8:30am ET/8:30pm SGT.
ASLAN PHARMACEUTICALS GRANTED ORPHAN DRUG DESIGNATION BY THE FDA FOR ASLAN003 FOR THE TREATMENT OF ACUTE MYELOID LEUKAEMIA
ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that the US Food and Drug Administration (FDA) has granted ASLAN003 Orphan Drug Designation (ODD) as a treatment for acute myeloid leukaemia (AML).
ASLAN Pharmaceuticals Completes Recruitment for Global Phase 2 Study for Varlitinib in First Line Gastric Cancer
ASLAN Pharmaceuticals, a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the completion of recruitment of 52 patients for the phase 2 part of its global phase 2/3 study investigating varlitinib as first line therapy in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients.
ASLAN Pharmaceuticals reported financial results for the quarter ended 30 June 2018 and provided an update on its clinical activities.
ASLAN Pharmaceuticals Submits Clinical Trial Authorisation Application for First in Man Studies for ASLAN004
ASLAN Pharmaceuticals announced the submission of a clinical trial authorisation application with the Singapore Health Sciences Authority (HSA) to initiate a phase 1 trial of ASLAN004.
Mereo pulled its planned initial public offering (IPO) on the Nasdaq Global Market, saying market conditions were not in the best interests of its shareholders. The company’s statement is getting some pushback from investors and analysts.
The conference is organised by the Cholangiocarcinoma Foundation and will be held from 31 January to 2 February 2018.
Mr. Doyle will assume the role in February 2018 and will be based at ASLAN’s offices in Shanghai.
The commercialisation of varlitinib in China is expected to begin approximately one year earlier than previously anticipated following recent discussions with the CFDA regarding its planned clinical development strategy for varlitinib in biliary tract cancer.
ASLAN Pharma today announced that commercialisation of varlitinib in China.
Carl Firth, Ph.D., CEO, will present an overview of the company at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 10:30 a.m. PT.
ASLAN Pharmaceuticals Pays $129M to Acquire Full Global Commercial Rights for Varlitinib From Arr...
1/3/2018The new licensing agreement replaces the prior licensing agreement signed in 2011 to develop and sublicense varlitinib, which did not grant commercial rights to ASLAN.
The new licensing agreement replaces the prior licensing agreement signed in 2011 to develop and sublicense varlitinib, which did not grant commercial rights to ASLAN.
ASLAN Pharma today announced that an abstract presented at ESMO Asia 2017 on data from its Phase 2 clinical trial of varlitinib in metastatic HER2-positive breast cancer patients won the Best Poster Award in the breast cancer, metastatic category.
ASLAN Pharma will host its first R&D day in Taipei, Taiwan, on 29 November 2017.
ASLAN Pharma Received IND Approval in Singapore to Initiate Phase II Study of ASLAN003 in Acute Myeloid Leukaemia
The phase II trial is a dose optimisation study, and the primary outcome is to determine the optimum monotherapy dose of ASLAN003 including efficacy evaluated by OCRR.
ASLAN Pharma today announced that it will be presenting data from its phase II trial of varlitinib in metastatic HER2-positive breast cancer patients at the ESMO Asia Congress 2017.